Healthcare provider profile · identity verified

Samuel Wasmann

Internal Medicine · BEAVERTON, OR · NPI 1376754515

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	677	185
Lisinopril	Lisinopril	470	139
Rosuvastatin Calcium	Rosuvastatin Calcium	418	132
Amlodipine Besylate	Amlodipine Besylate	354	103
Losartan Potassium	Losartan Potassium	353	108
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	295	34
Levothyroxine Sodium	Levothyroxine Sodium	267	66
Metformin Hcl	Metformin Hcl	246	70
Tamsulosin Hcl	Tamsulosin Hcl	235	69
Oxycodone Hcl	Oxycodone Hcl	209	37
Simvastatin	Simvastatin	201	61
Metoprolol Tartrate	Metoprolol Tartrate	197	57
Trazodone Hcl	Trazodone Hcl	195	48
Gabapentin	Gabapentin	166	46
Pradaxa	Dabigatran Etexilate Mesylate	153	48
Albuterol Sulfate Hfa	Albuterol Sulfate	134	55
Glipizide	Glipizide	127	35
Metformin Hcl Er	Metformin Hcl	127	39
Fluoxetine Hcl	Fluoxetine Hcl	124	38
Hydrochlorothiazide	Hydrochlorothiazide	104	33
Atenolol	Atenolol	101	29
Jardiance	Empagliflozin	98	27
Potassium Chloride	Potassium Chloride	95	36
Metoprolol Succinate	Metoprolol Succinate	86	28
Alendronate Sodium	Alendronate Sodium	84	26
Omeprazole	Omeprazole	83	20
Furosemide	Furosemide	80	31
Allopurinol	Allopurinol	74	21
Clopidogrel	Clopidogrel Bisulfate	70	19
Ozempic	Semaglutide	69	12
Spironolactone	Spironolactone	66	23
Pantoprazole Sodium	Pantoprazole Sodium	62	20
Warfarin Sodium	Warfarin Sodium	62	18
Eliquis	Apixaban	59	13
Humulin N	Insulin Nph Human Isophane	59	21
Finasteride	Finasteride	56	14
Duloxetine Hcl	Duloxetine Hcl	54	15
Pravastatin Sodium	Pravastatin Sodium	54	17
Sertraline Hcl	Sertraline Hcl	54	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	53	18
Carvedilol	Carvedilol	46	15
Donepezil Hcl	Donepezil Hcl	45	14
Fluticasone Propionate	Fluticasone Propionate	45	13
Bupropion Xl	Bupropion Hcl	44	12
Mirtazapine	Mirtazapine	44	suppressed
Acyclovir	Acyclovir	43	13
Terazosin Hcl	Terazosin Hcl	43	12
Citalopram Hbr	Citalopram Hydrobromide	42	suppressed
Morphine Sulfate Er	Morphine Sulfate	42	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	41	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	39	12
Propranolol Hcl	Propranolol Hcl	39	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	35	11
Prednisone	Prednisone	33	27
Triamcinolone Acetonide	Triamcinolone Acetonide	31	15
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	30	12
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Torsemide	Torsemide	29	suppressed
Humulin R	Insulin Regular, Human	28	suppressed
Meloxicam	Meloxicam	27	11
Wixela Inhub	Fluticasone Propion/Salmeterol	27	suppressed
Chlorthalidone	Chlorthalidone	26	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	25	suppressed
Ondansetron Odt	Ondansetron	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Azelastine Hcl	Azelastine Hcl	23	11
Estradiol	Estradiol	23	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	23	suppressed
Alvesco	Ciclesonide	22	11
Famotidine	Famotidine	22	suppressed
Lamotrigine	Lamotrigine	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Nitroglycerin	Nitroglycerin	22	11
Arexvy	Rsvpref3 Antigen/As01e/Pf	21	21
Diazepam	Diazepam	21	suppressed
Buspirone Hcl	Buspirone Hcl	20	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Lactulose	Lactulose	19	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	19	18
Tramadol Hcl	Tramadol Hcl	19	suppressed
Valsartan	Valsartan	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	17	17
Valacyclovir	Valacyclovir Hcl	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Pregabalin	Pregabalin	15	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	14	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Morphine Sulfate	Morphine Sulfate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	12
Fenofibrate	Fenofibrate	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	12	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Methylphenidate Hcl Er (Cd)	Methylphenidate Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Risperidone	Risperidone	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	11
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error